Mettler-Toledo International Inc. (0K10.L)
USD 1085.39
(2.02%)
USD 1085.39
(2.02%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.78 Billion USD | -3.35% |
| 2022 | 3.91 Billion USD | 5.43% |
| 2021 | 3.71 Billion USD | 20.51% |
| 2020 | 3.08 Billion USD | 2.54% |
| 2019 | 3 Billion USD | 2.49% |
| 2018 | 2.93 Billion USD | 7.73% |
| 2017 | 2.72 Billion USD | 8.64% |
| 2016 | 2.5 Billion USD | 4.71% |
| 2015 | 2.39 Billion USD | -3.64% |
| 2014 | 2.48 Billion USD | 4.5% |
| 2013 | 2.37 Billion USD | 1.6% |
| 2012 | 2.34 Billion USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 946.75 Million USD | 2.25% |
| 2024 Q1 | 925.94 Million USD | -0.97% |
| 2023 Q3 | 942.46 Million USD | -4.04% |
| 2023 Q1 | 928.73 Million USD | -12.19% |
| 2023 Q4 | 934.99 Million USD | -0.79% |
| 2023 Q2 | 982.11 Million USD | 5.75% |
| 2023 FY | 3.78 Billion USD | -3.35% |
| 2022 FY | 3.91 Billion USD | 5.43% |
| 2022 Q3 | 985.84 Million USD | 0.76% |
| 2022 Q2 | 978.38 Million USD | 8.98% |
| 2022 Q1 | 897.79 Million USD | -13.44% |
| 2022 Q4 | 1.05 Billion USD | 7.29% |
| 2021 Q3 | 951.95 Million USD | 2.99% |
| 2021 Q4 | 1.03 Billion USD | 8.96% |
| 2021 Q1 | 804.39 Million USD | -14.24% |
| 2021 Q2 | 924.35 Million USD | 14.91% |
| 2021 FY | 3.71 Billion USD | 20.51% |
| 2020 Q2 | 690.67 Million USD | 6.39% |
| 2020 Q4 | 937.98 Million USD | 16.18% |
| 2020 FY | 3.08 Billion USD | 2.54% |
| 2020 Q1 | 649.16 Million USD | -23.08% |
| 2020 Q3 | 807.35 Million USD | 16.89% |
| 2019 FY | 3 Billion USD | 2.49% |
| 2019 Q4 | 843.96 Million USD | 11.95% |
| 2019 Q3 | 753.86 Million USD | 3.08% |
| 2019 Q2 | 731.36 Million USD | 7.64% |
| 2019 Q1 | 679.45 Million USD | -16.93% |
| 2018 Q1 | 660.82 Million USD | -15.06% |
| 2018 Q3 | 734.84 Million USD | 1.78% |
| 2018 FY | 2.93 Billion USD | 7.73% |
| 2018 Q2 | 721.99 Million USD | 9.26% |
| 2018 Q4 | 817.92 Million USD | 11.31% |
| 2017 FY | 2.72 Billion USD | 8.64% |
| 2017 Q2 | 653.65 Million USD | 9.94% |
| 2017 Q4 | 778.03 Million USD | 11.34% |
| 2017 Q3 | 698.79 Million USD | 6.91% |
| 2017 Q1 | 594.56 Million USD | -16.22% |
| 2016 Q4 | 709.69 Million USD | 9.08% |
| 2016 FY | 2.5 Billion USD | 4.71% |
| 2016 Q3 | 650.59 Million USD | 6.96% |
| 2016 Q2 | 608.28 Million USD | 12.71% |
| 2016 Q1 | 539.67 Million USD | -19.87% |
| 2015 Q2 | 582.05 Million USD | 8.65% |
| 2015 Q3 | 604.15 Million USD | 3.8% |
| 2015 FY | 2.39 Billion USD | -3.64% |
| 2015 Q1 | 535.7 Million USD | -23.19% |
| 2015 Q4 | 673.53 Million USD | 11.48% |
| 2014 Q4 | 697.42 Million USD | 10.86% |
| 2014 FY | 2.48 Billion USD | 4.5% |
| 2014 Q1 | 550.62 Million USD | -19.53% |
| 2014 Q2 | 608.83 Million USD | 10.57% |
| 2014 Q3 | 629.1 Million USD | 3.33% |
| 2013 Q2 | 578.68 Million USD | 10.36% |
| 2013 Q3 | 591.68 Million USD | 2.25% |
| 2013 Q4 | 684.25 Million USD | 15.64% |
| 2013 FY | 2.37 Billion USD | 1.6% |
| 2013 Q1 | 524.35 Million USD | -20.22% |
| 2012 FY | 2.34 Billion USD | 0.0% |
| 2012 Q4 | 657.29 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -23811.563% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -108137.4% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -12022.977% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -14023.361% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -44088.837% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -17967.097% |
| Imunon, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 232.28 Million USD | -1530.895% |
| Editas Medicine, Inc. | 78.12 Million USD | -4749.16% |
| FibroGen, Inc. | 147.75 Million USD | -2463.965% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -318513.036% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -100.748% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -204.689% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -523.568% |
| Verastem, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 8.54 Billion USD | 55.661% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 61.615% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -2049.615% |
| Homology Medicines, Inc. | -6.65 Million USD | 57058.487% |
| Nektar Therapeutics | 90.12 Million USD | -4103.534% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 18.629% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -3156.407% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 97.434% |
| Illumina, Inc. | 4.5 Billion USD | 15.89% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 91.161% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 74.718% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -2881.887% |
| Waters Corporation | 2.95 Billion USD | -28.139% |
| Biogen Inc. | 9.83 Billion USD | 61.484% |
| Evolus, Inc. | 202.08 Million USD | -1774.612% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| bluebird bio, Inc. | 29.49 Million USD | -12743.031% |
| Geron Corporation | 237 Thousand USD | -1598342.616% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -107.205% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -848.605% |
| Myriad Genetics, Inc. | 678.4 Million USD | -458.418% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -10343.305% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -56.592% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 71.12% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 44.559% |
| OPKO Health, Inc. | 863.49 Million USD | -338.718% |
| Exelixis, Inc. | 1.83 Billion USD | -106.988% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -685.345% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -1299.966% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -380.965% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -356.834% |
| Blueprint Medicines Corporation | 249.38 Million USD | -1419.091% |
| Insmed Incorporated | 305.2 Million USD | -1141.222% |
| TG Therapeutics, Inc. | 233.66 Million USD | -1521.277% |
| Incyte Corporation | 3.69 Billion USD | -2.507% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -261.032% |